In vivo localization of [111In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector

Clinical Cancer Research

Volumn 5, Issue 2, 1999, Pages 383-393

  Rogers, Buck E ^b   McLean, Stephanie F ^b   Kirkman, Richard L ^b   Della Manna, Debbie ^b   Bright, Sheila J ^b   Olsen, Christine C ^b   Myracle, Angela D ^b   Mayo, Matthew S ^c   Curiel, David T ^a,c   Buchsbaum, Donald J ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b The University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTETREOTIDE IN 111; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR; VIRUS VECTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; INDIUM; MESSENGER RNA; OCTREOTIDE; PENTETIC ACID; SDZ 215 811; SDZ 215-811; SOMATOSTATIN RECEPTOR 2;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; HUMAN; HUMAN CELL; MOUSE; OVARY TUMOR; PRIORITY JOURNAL; TUMOR LOCALIZATION; XENOGRAFT; ANIMAL; BINDING COMPETITION; BIOSYNTHESIS; CANCER TRANSPLANTATION; FEMALE; GENE VECTOR; GENETICS; METABOLISM; NUDE MOUSE;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BINDING, COMPETITIVE; FEMALE; GENETIC VECTORS; HUMANS; INDIUM RADIOISOTOPES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OCTREOTIDE; OVARIAN NEOPLASMS; PENTETIC ACID; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER;

EID: 0032588961     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics. CA Cancer J. Clin., 48: 6-29, 1998.
2. Markman, M., Reichman, B., Hakes, T., Curtin, J., Jones, W., Lewis, J. L., Jr., Barakat, R., Rubin, S., Mychalczak, B., Saigo, P., Almadrones, L., and Hoskins, W. Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer (Phila.), 71: 1565-1570, 1993.
3. Hird, V., Maraveyas, A., Snook, D., Dhokia, B., Soutter, W. P., Meares, C., Stewart, J. S., Mason, P., Lambert, H. E., and Epenetos, A. A. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer, 68: 403-406, 1993.
4. Fein, D. A., Morgan, L. S., Marcus, R. B., Jr., Mendenhall, W. M., Sombeck, M. D., Freeman, D. E., and Million, R. R. Stage III ovarian carcinoma: an analysis of treatment results and complications following hyperfractionated abdominopelvic irradiation for salvage. Int. J. Radiat. Oncol. Biol. Phys., 29: 169-176, 1994.
5. Piver, M. S., Recio, F. O., Baker, T. R., and Driscoll, D. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer. Cancer (Phila.), 73: 1693-1698, 1994.
6. Meredith, R. F., Partridge, E. E., Alvarez, R. D., Khazaeli, M. B., Plott, G., Russell, C. D., Wheeler, R. H., Liu, T., Grizzle, W. E., Schlom, J., and LoBuglio, A. F. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med., 37: 1491-1496, 1996.
7. 177Lu-CC49: a phase I/II study. Gynecol. Oncol., 65: 94-101, 1997.
8. Knox, S. J. Overview of studies on experimental radioimmunotherapy. Cancer Res., 55 (Suppl.): 5832s-5836s, 1995.
9. Buchsbaum, D. J. Experimental radioimmunotherapy and methods to increase therapeutic efficacy. In: D. M. Goldenberg (ed.) Cancer Therapy with Radiolabeled Antibodies, pp. 115-140. Boca Raton: CRC Press, 1995.
10. Hand, P. H., Robbins, P. F., Salgaller, M. L., Poole, D. J., and Schlom, J. Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies. Cancer Immunol. Immunother., 36: 65-75, 1993.
11. Hinuma, S., Hosoya, M., Ogi, K., Tanaka, H., Nagai, Y., and Onda, H, Molecular cloning and functional expression of a human thyrotropin-releasing hormone (TRH) receptor gene. Biochim. Biophys. Acta, 1219: 251-259, 1994.
12. Falck-Pedersen, E., Heinflink, M., Alvira, M., Nussenzveig, D. R., and Gershengorn, M. C. Expression of thyrotropin-releasing hormone receptors by adenovirus-mediated gene transfer reveals that thyrotropin-releasing hormone desensitization is cell specific. Mol. Pharmacol., 45: 684-689, 1994.
13. Raben, D., Buchsbaum, D. J., Khazaeli, M. B., Rosenfeld, M. E., Gillespie, G. Y., Grizzle, W. E., Liu, T., and Curiel, D. T. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Ther., 3: 567-580, 1996.
14. Buchsbaum, D. J., Raben, D., Stackhouse, M. A., Khazaeli, M. B., Rogers, B. E., Rosenfeld, M. E., Liu, T., and Curiel, D. T. Approaches to enhance cancer radiotherapy employing gene transfer methods. Gene Ther., 3: 1042-1068, 1996.
15. 2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer. J. Nucl. Med., 38: 1221-1229, 1997.
16. Rogers, B. E., Curiel, D. T., Mayo, M. S., Laffoon, K., Bright, S., and Buchsbaum, D. J. Tumor localization of a radiolabeled bombesin analogue in mice bearing ovarian tumors induced to express the gastrin releasing peptide receptor by an adenoviral vector. Cancer (Phila.), 80 (Suppl.): 2419-2424, 1997.
17. Rosenfeld, M. E., Rogers, B. E., Khazaeli, M. B., Mikheeva, G., Raben, D., Mayo, M. S., Curiel, D. T., and Buchsbaum, D. J. Adenoviral mediated delivery of gastrin releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo. Clin. Cancer Res., 3: 1187-1194, 1997.
18. 99mTc-P829. Cancer Res., 58: 1850-1859, 1998.
19. Douglas, J. T., Rogers, B. E., Rosenfeld, M. E., Michael, S. I., Feng, M., and Curiel, D. T. Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotech., 14: 1574-1578, 1996.
20. Goldman, C. K., Rogers, B. E., Douglas, J. T., Sosnowski, B. A., Ying, W., Siegal, G. P., Baird, A., Campain, J. A., and Curiel, D. T. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res., 57: 1447-1451, 1997.
21. Rogers, B. E., Douglas, J. T., Sosnowski, B. A., Ying, W., Pierce, G., Buchsbaum, D. J., Della Manna, D., Baird, A., and Curiel, D. T. Enhanced in vivo gene delivery to human ovarian cancer xenografts utilizing a tropism-modified adenovirus vector. Tumor Targeting, 3: 25-31, 1998.
22. Rancourt, C., Rogers, B. E., Sosnowski, B. A., Wang, M., Piche, A., Pierce, G. F., Alvarez, R. D., Siegal, G. P., Douglas, J. T., and Curiel, D. T. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res., 4: 2455-2461, 1998.
23. Miller, C. R., Buchsbaum, D. J., Reynolds, P. N., Douglas, J. T., Gillespie, G. Y., Mayo, M. S., Raben, D., and Curiel, D. T. Differential susceptibility of primary and established human glioma cells to adeno-virus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-dependent gene transfer. Cancer Res., 58: 5738-5748, 1998.
24. Wickham, T. J., Roelvink, P. W., Brough, D. W., and Kovesdi, I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat. Biotech., 14: 1570-1573, 1996.
25. Krasnykh, V. N., Mikheeva, G. V., Douglas, J. T., and Curiel, D. T. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol., 70: 6839-6846, 1996.
26. Lan, K. H., Kanai, F., Shiratori, Y., Ohashi, M., Tanaka, T., Okudaira, T., Yoshida, Y., Hamada, H., and Omata, M. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res., 57: 4279-4284, 1997.
27. Stackhouse, M. A., Buchsbaum, D. J., Kancharla, S. R., Grimes, C., Laffoon, K., Pederson, L. C., and Curiel, D. T. Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. Cancer Gene Ther., in press, 1999.
28. Smith-Jones, P. M., Stolz, B., Albert, R., Ruser, G., Macke, H., Briner, U., Tolcsvai, L., Weckbecker, G., and Bruns, C. Synthesis, radiolabeling, and evaluation of DTPA/octreotide conjugates for radio-therapy. J. Labelled Compd. Radiopharm., 37: 499-501, 1995.
29. Wiseman, G. A., and Kvols, L. K. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin. Nucl. Med., 25; 272-278, 1995.
30. Anderson, C. J., Jones, L. A., Bass, L. A., Sherman, E. L. C., McCarthy, D. W., Cutler, P. D., Lanahan, M. V., Cristel, M. E., Lewis, J. S., and Schwarz, S. W. Radiotherapy, toxicity, and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J. Nucl. Med., 39: 1944-1951, 1998.
31. 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Int. J. Cancer, 65: 214-220, 1996.
32. 90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumors. Eur. J. Nucl. Med., 25: 668-674, 1998.
33. Volkert, W. A., Goeckeler, W. F., Ehrhardt, G. J., and Ketring, A. R. Therapeutic radionuclides: production and decay property considerations. J. Nucl. Med., 32: 174-185, 1991.
34. Yorke, E. D., Beaumier, P. L., Wessels, B. W., Fritzberg, A. R., and Morgan, A. C. Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics. Nucl. Med. Biol., 18: 827-835, 1991.
35. Woltering, E. A., O'Dorisio, M. S., and O'Dorisio, T. M. The role of radiolabeled somatostatin analogs in the management of cancer patients. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Principles and Practice of Oncology, Ed. 4, Vol. 9, pp. 1-16. Philadelphia: Lippincott-Raven, 1995.
36. Krenning, E. P., Bakker, W. H., Kooij, P. P. M., Breeman, W. A. P., Oei, H. Y., de Jong, M., Reubi, J. C., Visser, T. J., Bruns, C., Kwekkeboom, D. J., Reijs, A. E. M., van Hagen, P. M., Koper, J. W., and Lamberts, S. W. J. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J. Nucl. Med., 33: 652-658. 1992.
37. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med., 20: 716-731, 1993.
38. Krenning, E. P., Kwekkeboom, D. J., Pauwels, S., Kvols, L. K., and Reubi, J. C. Somatostatin receptor scintigraphy. In: L. M. Freeman (ed.) Nuclear Medicine Annual, Vol. XI, pp. 1-50. New York: Raven Press, Ltd., 1995.
39. Briganti, V., Sestini, R., Orlando, C., Bernini, G., La Cava, G., Tamburini, A., Raggi, C. C., Serio, M., and Maggi, M. Imaging of Somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of Somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin. Cancer Res., 3: 2385-2391, 1997.
40. 1]-octreotide. A case history. Ann. NY Acad. Sci., 733: 496-506, 1994.
41. 1-octreotide in midgut carcinoid syndrome. J. Nucl. Med., 37: 1519-1521, 1996.
42. Krenning, E. P., Kooij, P. P., Pauwels, S., Breeman, W. A., Postema, P. T., De Herder, W. W., Valkema, R., and Kwekkeboom, D. J. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion, 57: 57-61, 1996.
43. 111Inpentetreotide: initial observations and future directions. Cancer J. Sci. Am., 4: 94-102, 1998.
44. Graham, F. L., and Prevec, L. Manipulation of adenovirus vectors. In: E. J. Murray (ed.), Methods in Molecular Biology: Gene Transfer and Expression Protocols, Vol. 7, pp. 109-128. Clifton, NJ: The Humana Press, Inc., 1991.
45. Yamada, Y., Post, S. R., Wang, K., Tager, H. S., Bell, G. I., and Seino, S. Cloning and functional characterization of a family of human and mouse Somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc. Natl. Acad. Sci. USA, 89: 251-255, 1992.
46. Weckbecker, G., Liu, R., Tolcsvai, L., and Bruns, C. Antiproliferative effects of the Somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res., 52: 4973-4978, 1992.
47. Taylor, J. E., Theveniau, M. A., Bashirzadeh, R., Reisine, T., and Eden, P. A. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides, 15: 1229-1236, 1994.
48. Buscail, L., Delesque, N., Esteve, J. P., Saint-Laurent, N., Prats, H., Clerc, P., Robberecht, P., Bell, G. I., Liebow, C., Schally, A. V., Vaysse, N., and Susini, C. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc. Natl. Acad. Sci. USA, 91: 2315-2319, 1994.
49. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108, 1973.
50. Duncan, J. R., Stephenson, M. T., Wu, H. P., and Anderson, C. J. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res., 57: 659-671, 1997.
51. Deshane, J., Siegal, G. P., Alvarez, R. D., Wang, M., Feng, M., Cabrera, G., Liu, T., Kay, M., and Curiel, D. T. Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest., 96: 2980-2989, 1995.
52. Brody, S. L., Jaffe, A., Han, S. K., Wersto, R. P., and Crystal, R. G. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum. Gene Ther., 5: 437-447, 1994.
53. Smythe, W. R., Kaiser, L. R., Hwang, H. C., Amin, K. M., Pilewski, J. M., Eck, S. J., Wilson, J. M., and Albelda, S. M. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann. Thorac. Surg., 57: 1395-1401, 1994.
54. de Jong, M., Rolleman, E. J., Bernard, B. F., Visser, T. J., Bakker, W. H., Breeman, W. A., and Krenning, E. P. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J. Nucl. Med., 37: 1388-1392, 1996.
55. Dong, J. Y., Wang, D., Van Ginkel, F. W., Pascual, D. W., and Frizzell, R. A. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum. Gene Ther., 7: 319-331, 1996.
56. Worgall, S., Wolff, G., Falck-Pedersen, E., and Crystal, R. G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther., 8: 37-44, 1997.